Yang Xiang to Recurrence
This is a "connection" page, showing publications Yang Xiang has written about Recurrence.
Connection Strength
0.154
-
Cheng H, Zong L, Kong Y, Wang X, Gu Y, Cang W, Zhao J, Wan X, Yang J, Xiang Y. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial. Lancet Oncol. 2021 11; 22(11):1609-1617.
Score: 0.154